Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo ¹H-Magnetic...

Area of Science:

• Neuro-oncology
• Medical Imaging
• Biomarker Discovery

Background:

• Isocitrate dehydrogenase (IDH) mutation status is critical for glioma diagnosis and treatment according to WHO 2021.
• Current methods involve invasive tumor biopsy (immunohistochemistry and sequencing).
• Non-invasive IDH status determination is needed for clinical routine, especially when biopsy is not feasible or for therapy monitoring.

Purpose of the Study:

• To validate a non-invasive method for predicting IDH mutation status in gliomas using ¹H-MRS and machine learning.
• To assess the method's reliability across different magnetic field strengths (1.5T vs. 3.0T) and technical conditions.

Main Methods:

• ¹H-magnetic resonance spectroscopy (¹H-MRS) data from an independent cohort of 67 glioma patients acquired at 1.5T.
• Application of the same machine learning analysis approach used in a previous 3.0T study.
• Validation of sensitivity and specificity using established statistical measures.

Main Results:

• The ¹H-MRS based approach achieved a sensitivity of 82.6% and a specificity of 72.7% in the independent 1.5T cohort.
• The method demonstrated robustness despite variations in technical conditions (scanner field strength).
• The findings confirm the reliability of the non-invasive prediction of IDH mutation status.

Conclusions:

• ¹H-MRS combined with machine learning provides a reliable, non-invasive tool for determining IDH mutation status in gliomas.
• This approach is suitable for routine clinical implementation with minimal effort and time.
• The method is independent of technical conditions, making it broadly applicable in everyday clinical practice for glioma diagnosis and management.